These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 23780820

  • 21. Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients.
    Kivelä JM, Kosola S, Peräsaari J, Mäkisalo H, Jalanko H, Holmberg C, Pakarinen MP, Lauronen J.
    Transpl Int; 2016 Apr; 29(4):494-505. PubMed ID: 26806435
    [Abstract] [Full Text] [Related]

  • 22. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
    Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Cardeau-Desangles I, Guitard J, Dörr G, Milongo D, Suc B, Duffas JP, Alric L, Bureau C, Guilbeau-Frugier C, Rostaing L, Kamar N.
    Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
    [Abstract] [Full Text] [Related]

  • 23. Immunoglobulin G subclass analysis of HLA donor specific antibodies in heart and renal transplant recipients.
    Cicciarelli JC, Kasahara N, Lemp NA, Adamson R, Dembitsky W, Browne B, Steinberg S.
    Clin Transpl; 2013 Dec; ():413-22. PubMed ID: 25095537
    [Abstract] [Full Text] [Related]

  • 24. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility.
    Castillo-Rama M, Castro MJ, Bernardo I, Meneu-Diaz JC, Elola-Olaso AM, Calleja-Antolin SM, Romo E, Morales P, Moreno E, Paz-Artal E.
    Liver Transpl; 2008 Apr; 14(4):554-62. PubMed ID: 18383092
    [Abstract] [Full Text] [Related]

  • 25. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P, Jin J, Everly MJ, Lin C, Terasaki PI, Chen J.
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [Abstract] [Full Text] [Related]

  • 26. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM, Patel SJ, Burns KM, Dilioglou S, Gaber LW, Knight RJ, Gaber AO, Land GA.
    Clin Transpl; 2011 Oct; ():351-8. PubMed ID: 22755430
    [Abstract] [Full Text] [Related]

  • 27. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation.
    Itescu S, Tung TC, Burke EM, Weinberg A, Moazami N, Artrip JH, Suciu-Foca N, Rose EA, Oz MC, Michler RE.
    Circulation; 1998 Aug 25; 98(8):786-93. PubMed ID: 9727549
    [Abstract] [Full Text] [Related]

  • 28. Anti-human leukocyte antigen immunization after early allograft nephrectomy.
    Del Bello A, Congy N, Sallusto F, Cardeau-Desangles I, Fort M, Esposito L, Guitard J, Cointault O, Lavayssière L, Nogier MB, Game X, Blancher A, Rostaing L, Kamar N.
    Transplantation; 2012 May 15; 93(9):936-41. PubMed ID: 22361471
    [Abstract] [Full Text] [Related]

  • 29. Pre-transplant donor-specific anti-human leukocyte antigen antibodies are associated with high risk of delayed graft function after renal transplantation.
    Peräsaari JP, Kyllönen LE, Salmela KT, Merenmies JM.
    Nephrol Dial Transplant; 2016 Apr 15; 31(4):672-8. PubMed ID: 26614272
    [Abstract] [Full Text] [Related]

  • 30. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts.
    Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S, Minamiguchi S, Maekawa T, Uemoto S, Haga H.
    Liver Transpl; 2012 Nov 15; 18(11):1333-42. PubMed ID: 22888064
    [Abstract] [Full Text] [Related]

  • 31. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
    Schutt R, Case J, Kurian SM, Spierling Bagsic SR, Barrick BL, Toll AE, Zhang Q, Reed EF, Quigley MM, Schaffer R, Fisher JS, Rice JC, Marsh CL.
    Transplant Proc; 2021 Apr 15; 53(3):950-961. PubMed ID: 33293041
    [Abstract] [Full Text] [Related]

  • 32. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure.
    Cai J, Terasaki PI, Anderson N, Lachmann N, Schönemann C.
    Transplantation; 2009 Jul 27; 88(2):226-30. PubMed ID: 19623018
    [Abstract] [Full Text] [Related]

  • 33. Diagnostics and treatment of a severe humoral rejection after liver transplantation: donor-specific antibodies as a still underestimated cause of graft failure.
    Rashidi-Alavijeh J, Heinold A, Willuweit K, Baba HA, Horn PA, Paul A, Witzke O, Gerken G, Herzer K.
    Z Gastroenterol; 2016 Jul 27; 54(7):647-52. PubMed ID: 27429102
    [Abstract] [Full Text] [Related]

  • 34. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL, Jin XB, Li XT, Wang HW, Lü JJ.
    Chin Med J (Engl); 2009 Feb 20; 122(4):420-6. PubMed ID: 19302748
    [Abstract] [Full Text] [Related]

  • 35. Human leukocyte antigen and adult living-donor liver transplantation outcomes: an analysis of the organ procurement and transplantation network database.
    Jakab SS, Navarro VJ, Colombe BW, Daskalakis C, Herrine SK, Rossi S.
    Liver Transpl; 2007 Oct 20; 13(10):1405-13. PubMed ID: 17902126
    [Abstract] [Full Text] [Related]

  • 36. Human leukocyte antigen crossmatch testing is important for liver retransplantation.
    Goh A, Scalamogna M, De Feo T, Poli F, Terasaki PI.
    Liver Transpl; 2010 Mar 20; 16(3):308-13. PubMed ID: 20209590
    [Abstract] [Full Text] [Related]

  • 37. The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients.
    Mujtaba MA, Goggins W, Lobashevsky A, Sharfuddin AA, Yaqub MS, Mishler DP, Brahmi Z, Higgins N, Milgrom MM, Diez A, Taber T.
    Clin Transplant; 2011 Mar 20; 25(1):E96-102. PubMed ID: 20977497
    [Abstract] [Full Text] [Related]

  • 38. Harmful effect of preformed anti-MICA antibodies on renal allograft evolution in early posttransplantation period.
    Sánchez-Zapardiel E, Castro-Panete MJ, Castillo-Rama M, Morales P, Lora-Pablos D, Valero-Hervás D, Ruiz-García R, Apaza J, Talayero P, Andrés A, Morales JM, Paz-Artal E.
    Transplantation; 2013 Jul 15; 96(1):70-8. PubMed ID: 23624543
    [Abstract] [Full Text] [Related]

  • 39. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M, Torio A, Mas V, Redondo D, Pérez-Sáez MJ, Mir M, Faura A, Guerra R, Montes-Ares O, Checa MD, Pascual J.
    Transpl Immunol; 2013 Dec 15; 29(1-4):28-33. PubMed ID: 23907088
    [Abstract] [Full Text] [Related]

  • 40. Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection.
    Jackups R, Canter C, Sweet SC, Mohanakumar T, Morris GP.
    J Clin Apher; 2013 Aug 15; 28(4):301-8. PubMed ID: 23426730
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.